- Home
- WAL vs DVAX Comparison
WAL vs DVAX Comparison
Compare WAL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAL
- DVAX
- Stock Information
- Founded
- WAL 1994
- DVAX 1996
- Country
- WAL United States
- DVAX United States
- Employees
- WAL N/A
- DVAX N/A
- Industry
- WAL Major Banks
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- WAL Finance
- DVAX Health Care
- Exchange
- WAL Nasdaq
- DVAX Nasdaq
- Market Cap
- WAL 10.1B
- DVAX 1.3B
- IPO Year
- WAL 2005
- DVAX 2004
- Fundamental
- Price
- WAL $88.88
- DVAX $9.57
- Analyst Decision
- WAL Strong Buy
- DVAX Buy
- Analyst Count
- WAL 13
- DVAX 4
- Target Price
- WAL $97.62
- DVAX $26.50
- AVG Volume (30 Days)
- WAL 1.0M
- DVAX 2.0M
- Earning Date
- WAL 10-16-2025
- DVAX 11-06-2025
- Dividend Yield
- WAL 1.71%
- DVAX N/A
- EPS Growth
- WAL 14.60
- DVAX N/A
- EPS
- WAL 7.61
- DVAX N/A
- Revenue
- WAL $3,120,700,000.00
- DVAX $316,268,000.00
- Revenue This Year
- WAL $14.78
- DVAX $23.23
- Revenue Next Year
- WAL $10.40
- DVAX $16.57
- P/E Ratio
- WAL $11.67
- DVAX N/A
- Revenue Growth
- WAL 10.46
- DVAX 26.66
- 52 Week Low
- WAL $57.05
- DVAX $9.20
- 52 Week High
- WAL $98.10
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- WAL 56.94
- DVAX 39.47
- Support Level
- WAL $85.43
- DVAX $9.20
- Resistance Level
- WAL $91.61
- DVAX $9.94
- Average True Range (ATR)
- WAL 2.27
- DVAX 0.30
- MACD
- WAL -0.37
- DVAX -0.04
- Stochastic Oscillator
- WAL 43.89
- DVAX 31.90
About WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.